Published in J Natl Cancer Inst on February 21, 2007
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist (2013) 1.54
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010) 1.52
Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter. Clin Cancer Res (2012) 1.41
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Breast cancer in young women. Breast Cancer Res (2010) 1.31
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol (2014) 1.13
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res (2010) 1.04
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev (2009) 1.00
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone (2009) 0.99
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One (2013) 0.98
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone (2014) 0.90
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer (2012) 0.89
Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep (2011) 0.88
Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clin Exp Metastasis (2015) 0.86
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol (2009) 0.85
Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp Metastasis (2012) 0.85
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis. PLoS One (2013) 0.84
Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study. Cancer Res Treat (2011) 0.82
Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci (2012) 0.82
Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells. J Korean Med Sci (2011) 0.81
Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int (2012) 0.81
Cigarette smoking and risk of lung metastasis from esophageal cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.81
15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss. PLoS One (2015) 0.80
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast Cancer Res (2008) 0.79
CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther (2011) 0.79
Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag (2007) 0.78
The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model. J Cancer Res Clin Oncol (2014) 0.78
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget (2015) 0.78
The evolving role of zoledronic acid in early breast cancer. Onco Targets Ther (2009) 0.77
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. Invest New Drugs (2015) 0.77
Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate! J Thorac Dis (2013) 0.76
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. Breast Cancer Res (2015) 0.75
In reply. Oncologist (2013) 0.75
Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment. Mol Med Rep (2016) 0.75
Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. J Bone Oncol (2017) 0.75
Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo. Oncotarget (2016) 0.75
Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. J Clin Med (2014) 0.75
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer (2015) 0.75
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone (2010) 0.75
Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. Sci Rep (2015) 0.75
Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag (2008) 0.75
Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium. Osteoporos Int (2009) 0.75
Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells. Clin Exp Metastasis (2016) 0.75
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol (2011) 2.61
A new social communication intervention for children with autism: pilot randomised controlled treatment study suggesting effectiveness. J Child Psychol Psychiatry (2004) 2.59
A global perspective on trends in nature-based tourism. PLoS Biol (2009) 2.58
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res (2002) 1.97
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
Diversity of noroviruses cocirculating in the north of England from 1998 to 2001. J Clin Microbiol (2004) 1.65
Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J (2002) 1.64
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res (2007) 1.63
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A (2006) 1.61
The conceptualization and measurement of therapeutic alliance: an empirical review. Clin Psychol Rev (2008) 1.56
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res (2007) 1.55
Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol (2011) 1.55
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res (2003) 1.55
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care (2014) 1.48
Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol (2012) 1.47
A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet (2011) 1.43
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med (2005) 1.39
Bisphosphonates in cancer therapy. Cancer Lett (2007) 1.36
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev (2011) 1.34
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Public health value of next-generation DNA sequencing of enterohemorrhagic Escherichia coli isolates from an outbreak. J Clin Microbiol (2012) 1.31
Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One (2011) 1.31
Quality of interaction between at-risk infants and caregiver at 12-15 months is associated with 3-year autism outcome. J Child Psychol Psychiatry (2012) 1.27
Parent-infant interaction in infant siblings at risk of autism. Res Dev Disabil (2012) 1.22
The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res (2011) 1.17
Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int J Cancer (2010) 1.16
A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15
Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol (2002) 1.15
Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS One (2010) 1.12
Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res (2005) 1.10
Molecular epidemiology of rotaviral infection in South Indian children with acute diarrhea from 1995-1996 to 1998-1999. J Med Virol (2002) 1.10
Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care (2008) 1.07
The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone (2004) 1.06
Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics (2013) 1.03
An exploratory study of the association between reactive attachment disorder and attachment narratives in early school-age children. J Child Psychol Psychiatry (2009) 1.03
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (2010) 1.03
The impact of maternal psychopathology on child-mother attachment. Arch Womens Ment Health (2009) 1.02
Service and wider societal costs of very young children with autism in the UK. J Autism Dev Disord (2012) 1.01
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone (2010) 1.01
2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem (2007) 1.01
Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol (2009) 1.01
Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res (2011) 1.00
A rapid method for identifying diversity within PCR amplicons using a heteroduplex mobility assay and synthetic polynucleotides: application to characterisation of dsRNA elements associated with Cryptosporidium. J Microbiol Methods (2003) 0.96
Conversational behaviour of children with Asperger syndrome and conduct disorder. J Child Psychol Psychiatry (2002) 0.96
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res (2004) 0.96
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain (2002) 0.95
Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer (2005) 0.95
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res (2008) 0.94
Restricted and repetitive behaviors in autism spectrum disorders and typical development: cross-sectional and longitudinal comparisons. J Autism Dev Disord (2014) 0.94
Autism spectrum disorder profile in neurofibromatosis type I. J Autism Dev Disord (2015) 0.93
Treatment mechanism in the MRC preschool autism communication trial: implications for study design and parent-focussed therapy for children. J Child Psychol Psychiatry (2014) 0.93
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res (2012) 0.93
Reactive attachment disorder following early maltreatment: systematic evidence beyond the institution. J Abnorm Child Psychol (2013) 0.93
Characterisation of norovirus strains in rural Ghanaian children with acute diarrhoea. J Med Virol (2006) 0.92
Methods for the detection and characterisation of noroviruses associated with outbreaks of gastroenteritis: outbreaks occurring in the north-west of England during two norovirus seasons. J Med Virol (2004) 0.91
The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol (2010) 0.90
Do larger studies find smaller effects? The example of studies for the prevention of conduct disorder. Eur Child Adolesc Psychiatry (2008) 0.90
Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res (2008) 0.90
Transmigration: a new property of mature multinucleated osteoclasts. J Bone Miner Res (2006) 0.89
Evaluation of a one-tube RT-PCR system for detection of enteroviruses. J Clin Virol (2002) 0.88
TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res (2014) 0.88
The Social Communication Intervention Project: a randomized controlled trial of the effectiveness of speech and language therapy for school-age children who have pragmatic and social communication problems with or without autism spectrum disorder. Int J Lang Commun Disord (2012) 0.87
Call for a quality standard for sequence-based assays in clinical microbiology: necessity for quality assessment of sequences used in microbial identification and typing. J Clin Microbiol (2010) 0.87
Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res (2009) 0.87
HepSEQ: International Public Health Repository for Hepatitis B. Nucleic Acids Res (2006) 0.86
Dipeptide nitrile inhibitors of cathepsin K. Bioorg Med Chem Lett (2006) 0.86
Towards regional, error-bounded landscape carbon storage estimates for data-deficient areas of the world. PLoS One (2012) 0.85
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol (2011) 0.85
Social communication disorder outside autism? A diagnostic classification approach to delineating pragmatic language impairment, high functioning autism and specific language impairment. J Child Psychol Psychiatry (2013) 0.85
Brief report: mediation of treatment effect in a communication intervention for pre-school children with autism. J Autism Dev Disord (2012) 0.85
Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree? Inflamm Bowel Dis (2009) 0.84
A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One (2013) 0.83
Attachment narratives and behavioral and emotional symptoms in an ethnically diverse, at-risk sample. J Am Acad Child Adolesc Psychiatry (2008) 0.82
Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. J Proteome Res (2012) 0.82
Molecular epidemiological analysis of Cryptosporidium isolates from humans and animals by using a heteroduplex mobility assay and nucleic acid sequencing based on a small double-stranded RNA element. J Clin Microbiol (2003) 0.82
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia (2008) 0.82
The transmission of risk to children from mothers with schizophrenia: a developmental psychopathology model. Clin Psychol Rev (2007) 0.81
Infant neural sensitivity to dynamic eye gaze relates to quality of parent-infant interaction at 7-months in infants at risk for autism. J Autism Dev Disord (2015) 0.81
Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors. J Med Chem (2002) 0.81
A convenient clinically relevant model of human breast cancer bone metastasis. Clin Exp Metastasis (2007) 0.81
Quantifying peer interactions for research and clinical use: the Manchester Inventory for Playground Observation. Res Dev Disabil (2011) 0.79
Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem (2014) 0.79
Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int J Cancer (2014) 0.79
Brassinosteroids and analogs as neuroprotectors: synthesis and structure-activity relationships. Steroids (2011) 0.78
Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int (2010) 0.78
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics (2002) 0.78
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol (2003) 0.77
Secure attachment promotes the development of effortful control in boys. Attach Hum Dev (2015) 0.77
Autism Diagnostic Interview-Revised (ADI-R) Algorithms for Toddlers and Young Preschoolers: Application in a Non-US Sample of 1,104 Children. J Autism Dev Disord (2015) 0.77
[Does tumor angiogenesis play a role in bone metastatic process?]. Rev Med Suisse Romande (2004) 0.77